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Introduction
Cryptococcosis is an opportunistic fungal disease caused by Cryptococcus neoformans, 
an encapsulated dimorphic fungus. It has two subspecies: Cryptococcus neoformans var. 
neoformans and Cryptococcus neoformans var. gattii. Each subspecies cause disease in 
humans. C. neoformans var. neoformans has been connected to infection in immunosup-
pressed patients worldwide; C. neoformans var. gattii has been described in relation to 
infections in immunocompetent patients but its distribution is limited to tropical and 
subtropical countries. 
Infection occurs by inhaling the microorganism present in bird excrement, most com-
monly from pigeons. This produces an initial infection in the lungs, from where it can 
spread by hematogenous dissemination to other organs—mainly meninges and the cen-
tral nervous system—causing meningitis and encephalitis. [1,2] It also may remain latent 
and reactivate when immunity mechanisms fail. The most common manifestation of this 
fungus, both in immunosuppressed and immunocompetent patients, is neurological. 
Isolated pulmonary cryptococcosis occurs in approximately 10-30% of cases, and is more 
frequent in immunosuppressed patients. [3,4] Existing literature is focused on the HIV 
population, and descriptions of this disease in non-HIV patients are scarce. [5]
We present a patient with lymphoma on chemotherapy, with pulmonary and pleural in-
volvement with C. neoformans in the pleural fluid, with an unfavorable clinical course.
Clinical case
We present a 65-year-old patient, former smoker, with hypertension, gallstones, and 
stage III mantle cell lymphoma admitted with respiratory symptoms. He had under-
gone his first cycle of scheduled chemotherapy a week previously. He was admitted 
with worsening cough, expectoration, fever and concern for bacteremia. Upon physical 
examination, he was febrile and tachypneic. He had good bilateral air entry, bilateral 
isolated rhonchi, right-sided basilar crackles, and painless bilateral lateral cervical, su-
praclavicular, axillary and inguinal lymphadenopathy. His complete blood count (CBC) 
showed his hematocrit was 22 %, hemoglobin 7.8 g/dl, white blood cells 9,700/mm3 and 
platelets 522,000/mm3. Tests for HIV, Hepatitis B and Hepatitis C were negative. A chest 
computerized tomography (CT) scan was abnormal. (Figure 1)
The patient was initially felt to have hospital-acquired pneumonia. Blood cultures and 
sputum tests were ordered. An empiric treatment with piperacillin-tazobactam was 
started with a satisfactory clinical response. All cultures were initially negative. A week 
after admission, fever and hypoxemia recurred. A CT chest scan was repeated. (Figure 
2) 
A thoracentesis was performed, with results as follows:  slightly bloody pleural fluid, 
175/mm3 red blood cells, 740/mm3 white blood cells (lymphocyte predominant), glucose 
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Figure 1. Alveolar infiltrates with right upper, middle and lower lobe involvement, 
with consolidation areas, ground-glass areas and diffuse micronodules.
Figure 2. Bilateral pleural effusion with a right predominance and associated 
bibasilar consolidated areas and pleuro-pulmonary fibrous tracts.
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Pleural fluid culture tested negative for common organism pathogens and positive for Cryptococcus neoformans. Cryp-
tococcal antigen in the blood and fungal blood cultures remained negative.  Treatment with Amphotericin B was initi-
ated. The patient’s condition continued to worsen, with acute respiratory distress requiring orotracheal intubation and 
respiratory mechanical ventilation until he died due to multi-organ failure.  
Discussion
Pulmonary cryptococcosis may develop in immunocompetent or immunocompromised patients- such as those with 
HIV or other underlying medical conditions, such as lymphoma, leukemia, solid organs or bone marrow transplant 
recipients, systemic lupus erythematosus, sarcoidosis, diabetes mellitus, rheumatoid arthritis, chronic treatments with 
corticosteroids, immunomodulators and anti-TNF-α agents.
 
The clinical picture of cryptococcosis differs depending on the patient’s immune status. In immunocompetent pa-
tients, the infection is self-limited and minimally symptomatic; in the immunocompromised host, the disease can be 
severe and disseminated. 
 
Clinical manifestations of pulmonary cryptococcosis varies from mild symptoms such as cough, expectoration, pro-
longed febrile syndrome, weight loss, and anorexia to disseminated cryptococcosis involving several organs. This is 
why it is necessary to test for CNS involvement in immunosuppressed patients. [6,7]
There are three types of radiological patterns in pulmonary cryptococcosis:  (1) nodular mass, (2) consolidation and (3) 
reticulo-alveolar opacities. Nodules are the most frequent radiological finding in immunocompetent and immunosup-
pressed patients. These can be multiple, single, or cavitated with regular or irregular contours and may have confluent 
or be diffused in distribution. [8,9] Consolidations, reticular infiltrates, ground-glass opacities, a halo sign and medias-
tinal, or hilar adenopathy may also be found. Other less frequent findings are pleural effusion, cavitation and endobron-
chial lesions. After treatment of pulmonary cryptococcosis, bronchiectasis and fibrotic areas may appear. [10,11]
The yield from a pleural fluid culture for Cryptococcus is approximately 50%. Another method for diagnosis is the 
detection of Cryptococcal antigen in the pleural fluid. The title of antigenemia seems to be related to the route of 
dissemination—contiguous dissemination via subpleural pulmonary lesions is usually more common than bloodborne 
dissemination. [12]
In a review of patients with HIV and pulmonary cryptococcosis, 10% had pleural involvement and most cases were 
accompanied by disseminated cryptococcosis. There are only 50 reported cases of pleural cryptococcosis described in 
the literature. [3,12]
In a Young et al review, 14 of the 30 patients with pleural effusion due to Cryptococcus have a disease localized to the 
thorax and 16 have disseminated disease. Predisposing disease or immunosuppressive treatment were found in 17 pa-
tients. Cultures of pleural fluid for cryptococci were positive in 11 of 26 patients. (in the other 15 patients, the diagnosis 
was established by histopathological study of lung samples). [13] 
The guidelines from the Infectious Diseases Society of America (IDSA) for cryptococcal disease recommend treatment 
of disseminated disease with CNS involvement or severe pulmonary involvement with two weeks of Liposomal Am-
photericin and Flucytosine, continuing liposomal amphotericin B and flucytosine, then continuation with oral Fluco-
nazole for maintenance and suppression. When available, therapy doubled with amphotericin Band fluconazole may 
also be considered as an alternative when there is lack of access to flucytosine. [15] 
Conclusion
Pulmonary cryptococcosis is difficult to diagnose in non-AIDS immunosuppressed patients as the clinical and radio-
logical manifestations are atypical. Pleural involvement is uncommon. Clinical suspicion and invasive methods are 
necessary to establish the diagnosis and appropriate treatment.
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